← All trials
NCT04162535
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 26, 2018
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Iuliu Hatieganu University of Medicine and PharmacyLead sponsor
- Iuliu Hatieganu University of Medicine and PharmacyReponsible party - principal investigator
- Iuliu Hatieganu University of Medicine and PharmacyStudy director
- Prof. Dr. I. Chiricuta Institute of OncologyCollaborator
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.